Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.

Journal of the National Cancer Institute

Volumn 99, Issue 21, 2007, Pages 1613-1622

  Thall, Peter F ^a   Logothetis, Christopher ^a   Pagliaro, Lance C ^a   Wen, Sijin ^a   Brown, Melissa A ^a   Williams, Dallas ^a   Millikan, Randall E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; KETOCONAZOLE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE; VINCRISTINE;

AGED; ALGORITHM; ARTICLE; BLOOD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HUMAN; IMMUNOLOGY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME;

AGED; ALGORITHMS; ANDROGENS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CONFIDENCE INTERVALS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; ETOPOSIDE; HUMANS; KETOCONAZOLE; LOGISTIC MODELS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 36048985798     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm189     Document Type: Article

References (0)